Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Beam Therapeutics's total debt was $100.26M at Jun 30, 2026.
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $100.26M | – |
| Q1 FY2026 | Mar 31, 2026 | $100.19M | – |
See a number that looks wrong?